This brand name is authorized in United States. It is also authorized in Canada.
The drug LUMIFY contains one active pharmaceutical ingredient (API):
1
|
UNII
4S9CL2DY2H - BRIMONIDINE TARTRATE
|
|
Brimonidine is an alpha2-adrenergic receptor agonist that is 1000-fold more selective for the alpha2-adrenoceptor than the alpha1-adrenoreceptor. This selectivity results in no mydriasis and the absence of vasoconstriction in microvessels associated with human retinal xenografts. |
|
This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:
| ATC Group | Classification | |
|---|---|---|
| S01GA07 | S Sensory organs → S01 Ophthalmologicals → S01G Decongestants and antiallergics → S01GA Sympathomimetics used as decongestants | |
This drug has been assigned below unique identifiers within the countries it is being marketed:
| Country | Identification scheme | Identifier(s) |
|---|---|---|
| CA | Health Products and Food Branch | 02517698 |
| US | FDA, National Drug Code | 24208-537 |
© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.